NCT02912377View on ClinicalTrials.gov

Immunogenicity and Pharmacodynamic of B12019 and Neulasta® in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

96

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL

Neulasta, B12019

GCSF, Growth Colony Stimulating Factor

Trial Locations (1)

89231

Nuvisan GmbH, Neu-Ulm

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Cinfa Biotech

INDUSTRY